RU2011140858A - Конъюгаты гаптен-носитель, содержащие в качестве носителя бактериальные токсины, обладающие сигнальным пептидом, и их применение в иммуногенных композициях - Google Patents
Конъюгаты гаптен-носитель, содержащие в качестве носителя бактериальные токсины, обладающие сигнальным пептидом, и их применение в иммуногенных композициях Download PDFInfo
- Publication number
- RU2011140858A RU2011140858A RU2011140858/15A RU2011140858A RU2011140858A RU 2011140858 A RU2011140858 A RU 2011140858A RU 2011140858/15 A RU2011140858/15 A RU 2011140858/15A RU 2011140858 A RU2011140858 A RU 2011140858A RU 2011140858 A RU2011140858 A RU 2011140858A
- Authority
- RU
- Russia
- Prior art keywords
- immunogenic composition
- nicotine
- gly
- immune response
- signal peptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Addiction (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20962909P | 2009-03-09 | 2009-03-09 | |
| US61/209,629 | 2009-03-09 | ||
| PCT/EP2010/052997 WO2010103017A2 (en) | 2009-03-09 | 2010-03-09 | Hapten-carrier conjugates with bacterial toxins having a signal peptide as carrier and their use in immunogenic compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011140858A true RU2011140858A (ru) | 2013-04-20 |
Family
ID=42555592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011140858/15A RU2011140858A (ru) | 2009-03-09 | 2010-03-09 | Конъюгаты гаптен-носитель, содержащие в качестве носителя бактериальные токсины, обладающие сигнальным пептидом, и их применение в иммуногенных композициях |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20120100171A1 (https=) |
| EP (1) | EP2405943A2 (https=) |
| JP (1) | JP2012519724A (https=) |
| KR (1) | KR20120022760A (https=) |
| CN (1) | CN102427828A (https=) |
| CA (1) | CA2754592A1 (https=) |
| MX (1) | MX2011009359A (https=) |
| RU (1) | RU2011140858A (https=) |
| WO (1) | WO2010103017A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2355846A4 (en) * | 2008-09-03 | 2013-06-19 | Univ Michigan State | IMMUNOGENIC HEAT STABILIZER ESCHERICHIA COLI-ENTEROTOXIN |
| EP3756684A1 (en) | 2009-05-22 | 2020-12-30 | Genocea Biosciences, Inc. | Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response |
| EP2482838A4 (en) * | 2009-09-30 | 2013-04-10 | Toxcure Inc | USE OF BOTULINUM NEUROTOXIN FOR THE TREATMENT OF SUBSTANCE DEPENDENCE |
| JP6055776B2 (ja) | 2010-11-24 | 2016-12-27 | ジェノセア バイオサイエンシーズ， インコーポレイテッド | 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物及び方法 |
| US10160789B2 (en) | 2011-03-14 | 2018-12-25 | University Of Louisville Research Foundation, Inc. | Polypeptides having immunoactivating activity and methods of producing the same |
| EP3313866B1 (en) | 2015-06-29 | 2024-11-20 | University Of Louisville Research Foundation, Inc. | Compositions and methods for treating cancer and promoting wound healing |
| US10350288B2 (en) | 2016-09-28 | 2019-07-16 | Genocea Biosciences, Inc. | Methods and compositions for treating herpes |
| JP7118055B2 (ja) * | 2016-09-29 | 2022-08-15 | イプセン バイオファーム リミテッド | ハイブリッド神経毒 |
| EP3973253A4 (en) * | 2019-05-20 | 2022-08-10 | Siemens Healthcare Diagnostics, Inc. | PROCEDURE FOR DETECTING ABERRANTIC RESULTS DUE TO INCOMPLETE DELIVERY OF A POLYHAPTEN REAGENT IN IMMUNOASSAYS |
| US12280035B2 (en) | 2019-07-03 | 2025-04-22 | Intervet Inc. | Conjugated deoxynivalenol to protect against mycotoxicosis |
| US12343375B2 (en) | 2021-02-09 | 2025-07-01 | University Of Louisville Research Foundation, Inc. | Spray dried formulation of a cholera toxin B subunit variant |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5171568A (en) | 1984-04-06 | 1992-12-15 | Chiron Corporation | Recombinant herpes simplex gb-gd vaccine |
| US4883761A (en) | 1986-03-25 | 1989-11-28 | The United States Of America As Represented By The Department Of Health And Human Services | Pertussis toxin gene: cloning and expression of protective antigen |
| ES2061500T5 (es) | 1986-06-17 | 2003-05-16 | Chiron Corp | Diagnosis y vacunas de la hepatitis delta, su preparacion y uso. |
| JPH02500880A (ja) | 1987-11-18 | 1990-03-29 | カイロン コーポレイション | Ｎａｎｂｖの診断用薬およびワクチン |
| KR0185373B1 (ko) | 1989-03-17 | 1999-05-01 | 로버트 피. 블랙버언 | Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용 |
| ATE211772T1 (de) | 1989-05-18 | 2002-01-15 | Chiron Corp | Nanbv-diagnostika: polynukleotide, geeignet für reihenuntersuchungen auf hepatitis c-virus |
| US20020032316A1 (en) | 1995-03-31 | 2002-03-14 | Cantab Pharmaceuticals Research Limited | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
| US5773003A (en) * | 1995-03-31 | 1998-06-30 | Immulogic, Inc. | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
| US5876727A (en) | 1995-03-31 | 1999-03-02 | Immulogic Pharmaceutical Corporation | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
| FR2768747B1 (fr) | 1997-09-19 | 2000-12-01 | Pasteur Institut | Acides nucleiques, cellules recombinantes, et procede de preparation de compositions immunogenes |
| CN1231586C (zh) * | 2003-04-15 | 2005-12-14 | 中国科学院微生物研究所 | 一种多形汉逊酵母表达重组霍乱毒素b亚单位基因及其应用 |
| GB0325494D0 (en) * | 2003-10-31 | 2003-12-03 | Sbl Vaccin Ab | Expression system |
-
2010
- 2010-03-09 CA CA2754592A patent/CA2754592A1/en not_active Abandoned
- 2010-03-09 WO PCT/EP2010/052997 patent/WO2010103017A2/en not_active Ceased
- 2010-03-09 MX MX2011009359A patent/MX2011009359A/es not_active Application Discontinuation
- 2010-03-09 CN CN2010800175877A patent/CN102427828A/zh active Pending
- 2010-03-09 KR KR1020117023547A patent/KR20120022760A/ko not_active Withdrawn
- 2010-03-09 US US13/255,262 patent/US20120100171A1/en not_active Abandoned
- 2010-03-09 EP EP10706688A patent/EP2405943A2/en not_active Withdrawn
- 2010-03-09 RU RU2011140858/15A patent/RU2011140858A/ru not_active Application Discontinuation
- 2010-03-09 JP JP2011553432A patent/JP2012519724A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN102427828A (zh) | 2012-04-25 |
| WO2010103017A2 (en) | 2010-09-16 |
| WO2010103017A3 (en) | 2010-12-02 |
| CA2754592A1 (en) | 2010-09-16 |
| MX2011009359A (es) | 2011-12-16 |
| JP2012519724A (ja) | 2012-08-30 |
| KR20120022760A (ko) | 2012-03-12 |
| EP2405943A2 (en) | 2012-01-18 |
| US20120100171A1 (en) | 2012-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011140858A (ru) | Конъюгаты гаптен-носитель, содержащие в качестве носителя бактериальные токсины, обладающие сигнальным пептидом, и их применение в иммуногенных композициях | |
| HRP20201265T1 (hr) | Postupci liječenja i sprječavanja infekcija sa staphilococcus aureus i povezanih stanja | |
| Pérez et al. | New vaccines require potent adjuvants like AFPL1 and AFCo1 | |
| JP2017214397A5 (https=) | ||
| CN101745104B (zh) | 含有复合佐剂的结核亚单位疫苗 | |
| AU2014277027B2 (en) | Immunogenic composition for use in therapy | |
| US10576140B2 (en) | Cholera toxin chimera and its use as a staph vaccine | |
| Joshi et al. | Comparative immunogenicity and protective efficacy of different preparations of outer membrane proteins of Pasteurella multocida (B: 2) in a mouse model | |
| WO2010040847A3 (en) | Recombinant protein bodies as immunogen-specific adjuvants | |
| JP5237259B2 (ja) | 過剰産生黄色ブドウ球菌株の５型および８型莢膜多糖 | |
| López-Matas et al. | Depigmented allergoids reveal new epitopes with capacity to induce IgG blocking antibodies | |
| Amin et al. | Novel Klebsiella pneumoniae and Pseudomonas aeruginosa MAPS vaccine combining O polysaccharides and pathogen-specific proteins | |
| Ma et al. | Als3‐Th‐cell‐epitopes plus the novel combined adjuvants of CpG, MDP, and FIA synergistically enhanced the immune response of recombinant TRAP derived from Staphylococcus aureus in mice | |
| Arlian et al. | Mucosal immunization with a Staphylococcus aureus IsdA-cholera toxin A2/B chimera induces antigen-specific Th2-type responses in mice | |
| US8911748B2 (en) | Cholera toxin chimera and its use as a staph vaccine | |
| JP2016525507A5 (https=) | ||
| CN104587463A (zh) | 鱼类nkef-a重组蛋白对适应性体液免疫的活化效应及其应用 | |
| Sengupta et al. | A 20-kDa pilus protein with haemagglutination and intestinal adherence properties expressed by a clinical isolate of non-01 Vibrio cholerae | |
| AU2015359503B2 (en) | Method of treatment | |
| CN103212060B (zh) | 蛋白及其组合物与在制备预防、诊断或治疗ehec感染产品中的应用 | |
| Sumit Joshi et al. | Comparative immunogenicity and protective efficacy of different preparations of outer membrane proteins of Pasteurella multocida (B: 2) in a mouse model. | |
| RU2008131066A (ru) | Фармацевтическая композиция, содержащая белок nma0939 | |
| Misra | Development of a Cholera Toxin CTA 2/B Based Staphylococcus aureus Vaccine to Prevent Bovine Mastitis | |
| WO2004043286A3 (en) | Use of rmlt as a marker antigen for vaccines and as a synergistic adjuvant with amphigen | |
| Sharma et al. | EVALUATION OF WHOLE CELL AND FIMBRIAL Escherichia coli VACCINE IN MICE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20141016 |